SeaStar Medical's QUELIMMUNE Shows 65.1% 90-Day Survival in Pediatric AKI Study

• SeaStar Medical’s QUELIMMUNE fulfilled FDA post-approval study requirements for treating sepsis-associated acute kidney injury in pediatric patients.
• Hospitals can now use the therapy without the SAVE Registry’s research infrastructure, expanding access for critically ill children requiring renal replacement therapy.
• SAVE Registry results, already presented at ASN Kidney Week 2026, showed significantly improved survival compared with clinically aligned pediatric database cohorts.
• No device-related adverse events were reported among registry patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-034531), on November 03, 2026, and is solely responsible for the information contained therein.